ALT - Altimmune Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Altimmune Inc. (ALT) Class Action | Benzinga

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Altimmune, Inc. (NASDAQ:ALT) securities between December 1, 2023 and April 26, 2024. Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases. The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. GLP-1 agonists are medications that help lower blood sugar levels and promote weight loss.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug

According to the complaint, during the class period, defendants failed to disclose that: (i) Altimmune overstated the potential for pemvidutide to stand out from competing GLP-1 agonists based on the drug's efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial ...

ALT) Class Action>Full story available on Benzinga.com